18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Part A: Number of Participants With Dose Limiting Toxicities (DLTs)Primary· Up to 3 weeks
DLT: any death not clearly due to underlying disease/extraneous causes/Grade(Gr) \>=3 nonhematologic/Gr\>=4 hematologic toxicity that was probably/definitely related to any of study interventions, individually/combination that occurred during DLT observation period, except for any of following: Gr3 infusion-related reaction; Transient (\<=6hr) Gr3 flu-like symptoms/fever, controlled with medical management; Transient (\<=72hr) Gr3 fatigue, local reactions, headache, nausea/emesis; Gr3 diarrhea, skin toxicity, liver function test increase; Single laboratory values out of normal range and contro
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
0
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEsSecondary· Time from first dose of study treatment up to 230 days
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events that started or worsened after first dose of study intervent
TEAEs
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
3
Treatment-Related TEAEs
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
3
Part A: Number of Participants With Confirmed Best Overall Response (BOR)Secondary· Time from first dose of study treatment up to 230 days
Confirmed BOR according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and as assessed by an Investigator was defined as best response of any of the complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) recorded from the date of randomization until disease progression/ recurrence (taking the smallest measurement recorded since the start of treatment as reference). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions
Complete Response
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
0
Partial Response
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
0
Stable Disease
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
1
Progressive Disease
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
2
Part A: Progression-Free Survival (PFS)Secondary· Time from first dose of study treatment up to 230 days
PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and as assessed by an Investigator was defined as the time from date of randomization until date of the first observation of progressive disease (PD) or death due to any cause within 12 weeks of the last tumor assessment in the absence of documented PD, whichever occurs first. PD was defined as at least a 20% increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions.
Participant 1
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
1.9
Participant 2
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
2.1
Participant 3
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
6.1
Part A: Time to Progression (TTP)Secondary· Time from first dose of study treatment up to 230 days
TTP according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and assessed by an Investigator was defined as the time from first dose of study intervention until progression disease (PD). PD was defined as at least a 20% increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions. Participant wise data reported for this outcome measure.
Participant 1
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
1.9
Participant 2
Group
Value
95% CI
Part A: Carboplatin + M6620 + Avelumab
2.1
Adverse events — posted to ClinicalTrials.gov
Time frame: Time from first dose of study treatment up to 230 days.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03641547 — M6620 Plus Standard Treatment in Oesophageal and Other Cancer
· Phase 1
· completed
NCT02157792 — M6620 First in Human Study
· Phase 1
· completed
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
· Phase 4
· recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
· Phase 1
· recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
· Phase 3
· recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection
· NA
· recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
· Phase 1, PHASE2
· recruiting
Other EMD Serono Research & Development Institute, Inc. trials
Trials by the same sponsor.
NCT07355218 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
· Phase 3
· recruiting
NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
· Phase 3
· recruiting
NCT07166601 — M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid
· Phase 1
· recruiting
NCT07097259 — A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EMD Serono Research & Development Institute, Inc.
Last refreshed: 13 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704467.